Catherine Belle Meador, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 20 | 2024 | 13249 | 1.240 |
Why?
|
Drug Resistance, Neoplasm | 11 | 2024 | 5230 | 0.950 |
Why?
|
Small Cell Lung Carcinoma | 7 | 2024 | 421 | 0.910 |
Why?
|
Thoracic Neoplasms | 1 | 2023 | 265 | 0.720 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 5 | 2023 | 5248 | 0.700 |
Why?
|
Leadership | 2 | 2016 | 1372 | 0.550 |
Why?
|
Molecular Targeted Therapy | 3 | 2020 | 2805 | 0.500 |
Why?
|
Genotype | 3 | 2021 | 12959 | 0.500 |
Why?
|
Protein Kinase Inhibitors | 6 | 2021 | 5640 | 0.500 |
Why?
|
Antineoplastic Agents | 6 | 2021 | 13629 | 0.450 |
Why?
|
Mutation | 12 | 2024 | 29951 | 0.360 |
Why?
|
Biomedical Research | 2 | 2016 | 3421 | 0.360 |
Why?
|
MAP Kinase Signaling System | 2 | 2015 | 1483 | 0.320 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2015 | 2052 | 0.300 |
Why?
|
Acrylamides | 3 | 2017 | 260 | 0.250 |
Why?
|
Neoplasms | 4 | 2023 | 22066 | 0.240 |
Why?
|
Negotiating | 2 | 2016 | 148 | 0.240 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2359 | 0.230 |
Why?
|
Education, Medical | 1 | 2016 | 1728 | 0.230 |
Why?
|
Exodeoxyribonucleases | 1 | 2024 | 195 | 0.220 |
Why?
|
Epigenomics | 2 | 2024 | 936 | 0.190 |
Why?
|
Aniline Compounds | 3 | 2017 | 1068 | 0.190 |
Why?
|
Career Choice | 2 | 2016 | 755 | 0.170 |
Why?
|
Gene Amplification | 1 | 2024 | 1085 | 0.170 |
Why?
|
Paraneoplastic Syndromes, Nervous System | 1 | 2019 | 24 | 0.170 |
Why?
|
Biology | 1 | 2021 | 289 | 0.170 |
Why?
|
Tumor Microenvironment | 3 | 2024 | 3829 | 0.160 |
Why?
|
Genetic Variation | 1 | 2014 | 6540 | 0.160 |
Why?
|
Quinazolines | 2 | 2015 | 1363 | 0.160 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 242 | 0.150 |
Why?
|
Mice, Nude | 4 | 2017 | 3605 | 0.140 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2017 | 186 | 0.140 |
Why?
|
Receptor, EphA2 | 1 | 2016 | 41 | 0.130 |
Why?
|
Phosphoproteins | 1 | 2024 | 2441 | 0.130 |
Why?
|
Exons | 1 | 2021 | 2391 | 0.130 |
Why?
|
Colorectal Neoplasms | 1 | 2015 | 6856 | 0.120 |
Why?
|
src-Family Kinases | 1 | 2017 | 534 | 0.120 |
Why?
|
Group Processes | 1 | 2016 | 226 | 0.120 |
Why?
|
Humans | 26 | 2024 | 760276 | 0.110 |
Why?
|
Cell Line, Tumor | 7 | 2024 | 16908 | 0.110 |
Why?
|
Niacinamide | 1 | 2016 | 414 | 0.110 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1090 | 0.110 |
Why?
|
Professional Competence | 1 | 2016 | 431 | 0.100 |
Why?
|
Curriculum | 2 | 2016 | 3722 | 0.100 |
Why?
|
INDEL Mutation | 1 | 2013 | 266 | 0.100 |
Why?
|
Patient Admission | 1 | 2019 | 1384 | 0.100 |
Why?
|
Cell Lineage | 1 | 2020 | 2525 | 0.090 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2024 | 2823 | 0.090 |
Why?
|
Benzamides | 1 | 2016 | 1370 | 0.090 |
Why?
|
DNA, Neoplasm | 1 | 2015 | 1745 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2024 | 3584 | 0.080 |
Why?
|
Animals | 11 | 2024 | 167935 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2753 | 0.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11708 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1614 | 0.070 |
Why?
|
Piperazines | 1 | 2017 | 2520 | 0.070 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2015 | 2415 | 0.070 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14655 | 0.060 |
Why?
|
Genome, Human | 2 | 2015 | 4416 | 0.060 |
Why?
|
Octamer Transcription Factors | 1 | 2023 | 18 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3380 | 0.060 |
Why?
|
Mice | 8 | 2024 | 81212 | 0.050 |
Why?
|
Biopsy | 1 | 2015 | 6775 | 0.050 |
Why?
|
Lactates | 1 | 2023 | 404 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2016 | 10439 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2017 | 9274 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5395 | 0.050 |
Why?
|
Genetic Testing | 1 | 2014 | 3533 | 0.050 |
Why?
|
Chemokines | 1 | 2024 | 962 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2024 | 995 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2020 | 64968 | 0.040 |
Why?
|
Genomics | 1 | 2014 | 5790 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6310 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2024 | 8502 | 0.040 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2023 | 1137 | 0.040 |
Why?
|
Pneumonectomy | 1 | 2023 | 1110 | 0.030 |
Why?
|
Melanoma | 1 | 2014 | 5694 | 0.030 |
Why?
|
Heart Failure | 1 | 2019 | 11836 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2023 | 3531 | 0.030 |
Why?
|
Survival Rate | 2 | 2019 | 12806 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2015 | 717 | 0.030 |
Why?
|
Immunity, Innate | 1 | 2024 | 3046 | 0.030 |
Why?
|
Aged | 4 | 2019 | 169002 | 0.020 |
Why?
|
Drug Synergism | 1 | 2016 | 1755 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8551 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2024 | 3758 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4554 | 0.020 |
Why?
|
DNA Methylation | 1 | 2024 | 4374 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2015 | 1345 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2015 | 858 | 0.020 |
Why?
|
ras Proteins | 1 | 2015 | 1051 | 0.020 |
Why?
|
Male | 5 | 2024 | 359427 | 0.020 |
Why?
|
Transfection | 1 | 2017 | 5782 | 0.020 |
Why?
|
Signal Transduction | 3 | 2017 | 23366 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2023 | 11141 | 0.020 |
Why?
|
Macrophages | 1 | 2023 | 5746 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4637 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1820 | 0.020 |
Why?
|
Inpatients | 1 | 2019 | 2580 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2023 | 80311 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1729 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9283 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3329 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2015 | 6499 | 0.020 |
Why?
|
Lung | 1 | 2023 | 9988 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2013 | 2011 | 0.010 |
Why?
|
Female | 5 | 2024 | 391024 | 0.010 |
Why?
|
Transcription Factors | 1 | 2023 | 12100 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2019 | 58953 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2013 | 4717 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14481 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2013 | 3618 | 0.010 |
Why?
|
Middle Aged | 3 | 2019 | 220179 | 0.010 |
Why?
|
Apoptosis | 1 | 2016 | 9497 | 0.010 |
Why?
|
Prognosis | 1 | 2019 | 29640 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 24086 | 0.010 |
Why?
|
Time Factors | 1 | 2019 | 40141 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2017 | 39256 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 15765 | 0.010 |
Why?
|
Prospective Studies | 1 | 2017 | 54265 | 0.010 |
Why?
|
Risk Factors | 1 | 2019 | 74278 | 0.010 |
Why?
|
Adult | 1 | 2017 | 219843 | 0.000 |
Why?
|